Weidong Wei

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 4

Top Topics

Replacement Therapy

Signaling Pathway

Long Non Coding Rna

Top Venues

Clinical and translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Zhenchong Xiong, Lin Yang, Ning Li, Jianchang Fu, Peng Liu, Peng Sun, Weidong Wei, Xiaoming Xie
DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. Clinical and translational medicine 12 (12) (2022)
Zhenchong Xiong, Lin Yang, Ning Li, Jianchang Fu, Peng Liu, Peng Sun, Weidong Wei, Xiaoming Xie
DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. Clinical and translational medicine 12 (12) (2022)
Zhenchong Xiong, Lin Yang, Ning Li, Jianchang Fu, Peng Liu, Peng Sun, Weidong Wei, Xiaoming Xie
DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. Clinical and translational medicine 12 (12) (2022)
Yunting Jian, Lingzhi Kong, Hongyi Xu, Yawei Shi, Xinjian Huang, Wenjing Zhong, Shumei Huang, Yue Li, Dongni Shi, Yunyun Xiao, Muwen Yang, Siqi Li, Xiangfu Chen, Ying Ouyang, Yameng Hu, Xin Chen, Libing Song, Runyi Ye, Weidong Wei
Protein phosphatase 1 regulatory inhibitor subunit 14C promotes triple-negative breast cancer progression via sustaining inactive glycogen synthase kinase 3 beta. Clinical and translational medicine 12 (1) (2022)